Why sufferers from Alzheimer’s disease might have lower blood pressure
Forgetting your troubles can bring healthier hearts
Oxford, October 14, 2008 - A new study published in Bioscience Hypotheses, a recently launched Elsevier journal, proposes that some people suffering from Alzheimer’s disease experience a reduction in their high blood pressure because of cognitive decline.
Publications relating to dementia and blood pressure have been reviewed by the paper’s author Dr Sven Kurbel of the Osijek Medical Faculty in Croatia. The cognitive problems suffered by some Alzheimer’s patients have previously been put down to low blood pressure (arterial hypotension). The hypothesis put forward by Dr Kurbel is that the opposite is true. He suggests that as the patient’s memory fails, they forget the causes of anxiety and worry that was causing high blood pressure: failing memory causes hypotension, not visa versa
Hypertension itself is a cause of disease, including strokes, so paradoxically, Dr. Kurbel's hypothesis suggests, treatments which alleviate memory loss could affect other causes of illness. If this hypothesis is correct it could have a significant effect on the treatment of conditions such as metabolic syndrome, which involves increased weight and high blood pressure. Dr. Kurbel concludes that “An important question is would reduction of stressful memories and of stress exposure in everyday life help diminish the risk of getting hypertension or metabolic syndrome in the years to come.”
If confirmed by further studies, this will affect how doctors treat the elderly, helping to target drugs more effectively and reduce risks of stokes and heart attack It also suggests that heart disease could be substantially reduced in old people simply by making them happier about themselves and their lives.
Dr. William Bains, editor of Bioscience Hypotheses, said "This is a fascinating piece of lateral thinking, one with real health implications, and just the sort of stimulating, practical idea that we hoped Bioscience Hypotheses would be able to publish for other scientists to think about"
# # #About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media Contact:
+44 1865 843824